pnj.com wants to ensure the best experience for all of our readers, so we built our site to take advantage of the latest technology, making it faster and easier to use.
Unfortunately, your browser is not supported. Please download one of these browsers for the best experience on pnj.com
See the rest here:
Ascension Sacred Heart proposes to develop new medical office building - Pensacola News Journal
GONZALES - The former deputy of the Ascension Parish Assessor's Office was arrested Tuesday after he allegedly changed tax values for his personal property.
Jail records said 44-year-old Justin Champlin was booked for two counts of computer tampering, two counts of injuring public records and one count malfeasance in office.
The Gonzales Police Department said Champlin has been working at the assessor's office since 2012 and the issue happened while he was working as the deputy assessor.
The case is being turned over to the District Attorney's office.
View original post here:
If youve pulled Arlecchino, another 5-star banner added in Genshin Impact 4.6, youll want to Ascend her to max level as soon as possible to cash in on that Wish investment. The latest Pyro character will lead you on a hunt for Fatui-themed upgrades to make the most of her levels and Talent.
To perfect her build, heres every Ascension material youll need for Arlecchino and where to find it that includes requirements for her Talent boosts, too.
Arlecchino uses Fragments of a Golden Melody, which drop from the Legatus Golem world boss. You can find this world boss in the lost kingdom of Remuria, which you can access by following the World Quest that starts in the Fontanian island village of Petrichor.
Youll need 46 Fragments in total, which will take an average of 18 boss runs or about 720 Resin at World Level 8.
Arlecchino require Rainbow Roses, which grow around Fontaine. If you collect them with the Seed Dispensary gadget equipped, you can gather seeds to grow additional Rainbow Roses in your teapot.
You will need 168 Rainbow Roses to fully Ascend Arlecchino. Like other local specialties, Rainbow Roses respawn 48 hours after collecting them. There are only 81 Rainbow Roses in the overworld, so you may need to ask a friend if you can take theirs.
As a member of the Fatui, Arlecchino uses Fatui insignias to ascend. These drop from most Fatui enemies, including Cicin Mages, Pyro Agents, and all Skirmishers.
For maximum character levels, Arlecchino will need 18 Recruits Insignia, 30 Sergeants Insignia, and 36 Lieutenants Insignia. This doesnt include insignias needed for Talents.
Like other Pyro characters, Arlecchino uses red Agnidus Agates to Ascend. These do drop from her boss, the Legatus Golem, but they will come mixed with Geo gems. If youre short on Pyro gems, use Dust of Azoth to convert some from a different element.
Arlecchino will need 1 Agnidus Agate Sliver, 9 Fragments, 9 Chunks, and 6 Gemstones to fully Ascend.
Despite her Snezhnayan affiliation, Arlecchino uses Order Talent books from Fontaine. You can farm these from the Fontaine Talent domain on Wednesdays, Saturdays, and Sundays.
To level her Talents to 10/10/10, Arlecchino will need 9 brown books, 63 silver books, and 114 gold books. This translates to about 2,480 Resin, depending on your drop luck.
Fatui enemies can be found all over Teyvat. My favorite farming spots are the north side of Dragonspine and the northwest side of Seirai Island.
Fully leveling Arlecchinos Talents requires 18 Recruits Insignia, 66 Sergeants Insignia, and 93 Lieutenants Insignia. This doesnt include insignias needed for character Ascension.
Fading Candles drop from the new weekly boss in 4.6, The Knave. You can unlock this boss domain by completing Arlecchinos Story Quest, or you can quick-start the challenge from your Adventurers Handbook.
Arlecchino will need 18 Candles to fully level her Talents. This means around 8 weeks of farming, depending on your luck.
Continued here:
All Arlecchino Ascension and Talent materials in Genshin Impact - Destructoid
About Kiran
With over 20 years of experience in journalism, I ventured off to launch a new concept: 100% digital media news and called it Unfiltered with Kiran. What started as a single person launching a dream has now turned into a team with extremely dedicated journalists. We, as a team, are proud to serve each and every one of you!
Read more:
freep.com wants to ensure the best experience for all of our readers, so we built our site to take advantage of the latest technology, making it faster and easier to use.
Unfortunately, your browser is not supported. Please download one of these browsers for the best experience on freep.com
View post:
Doctors, nurses walk out on strike at Ascension St. John in Detroit - Detroit Free Press
weeklycitizen.com wants to ensure the best experience for all of our readers, so we built our site to take advantage of the latest technology, making it faster and easier to use.
Unfortunately, your browser is not supported. Please download one of these browsers for the best experience on weeklycitizen.com
Follow this link:
weeklycitizen.com wants to ensure the best experience for all of our readers, so we built our site to take advantage of the latest technology, making it faster and easier to use.
Unfortunately, your browser is not supported. Please download one of these browsers for the best experience on weeklycitizen.com
Read the original:
St. Amant Primary teachers implement ideas with Ascension Fund grants - Weekly Citizen
weeklycitizen.com wants to ensure the best experience for all of our readers, so we built our site to take advantage of the latest technology, making it faster and easier to use.
Unfortunately, your browser is not supported. Please download one of these browsers for the best experience on weeklycitizen.com
Read the original:
Ascension Parish food distribution event rescheduled for April 23 - Weekly Citizen
weeklycitizen.com wants to ensure the best experience for all of our readers, so we built our site to take advantage of the latest technology, making it faster and easier to use.
Unfortunately, your browser is not supported. Please download one of these browsers for the best experience on weeklycitizen.com
Continue reading here:
weeklycitizen.com wants to ensure the best experience for all of our readers, so we built our site to take advantage of the latest technology, making it faster and easier to use.
Unfortunately, your browser is not supported. Please download one of these browsers for the best experience on weeklycitizen.com
The rest is here:
St. Amant, Ascension Catholic reach softball state tournament - Weekly Citizen
After an incredibly powerful short movie and a ton of different promotional materials, The Knave is finally coming as playable in Genshin Impact. But before Arlecchino can display her true potential, youll need to farm for certain ascension materials first.
As a 5-star Pyro Polearm character, Arlecchino is far from being the first in this specific role. However, she brings some unique gameplay with her scythe-like attacks that sacrifice a portion of her HP. According to the official Genshin Impact Progression Calculator, this is what you need to level up her fully.
Arlecchino shares a lot of materials with her fellow Pyro Fatui and son Lyney. They even share the Rainbow Rose specialty for their ascension. The Insignia drops can all be obtained from various Fatui enemies across the map, so use the Adventurers Handbook to get their locations if you havent enough of these with you. However, her assigned World Boss is the Statue of Marble and Brass world boss, a new addition to the 4.6 version.
Related: Genshin Impacts New Metroidvania Web Event is Scratching My Hollow Knight Silksong Itch
More Fatui-related items here, so double down on farming those. Arlecchino uses the Order books from the Rhyming Rhythm domain in Fontaine to level up her talents, as well as the new items from her own Weekly Boss, The Knave. Sometimes you are your worst enemy, I guess. As of 4.1, players no longer need to advance through Story Quests to farm for bosses, so you can challenge her boss version from the get-go.
The hardest part is, without a doubt, getting enough Roses and Talent items, as these will take you most of your time/resin to accomplish. Not to mention the artifact grind for her build which is always a struggle, but very worth it in the end.
Here is the original post:
All Arlecchino Ascension Materials in Genshin Impact - The Escapist
weeklycitizen.com wants to ensure the best experience for all of our readers, so we built our site to take advantage of the latest technology, making it faster and easier to use.
Unfortunately, your browser is not supported. Please download one of these browsers for the best experience on weeklycitizen.com
Read more here:
Ascension Parish man pleads guilty to manslaughter in 2016 fatal shooting of fiance - Weekly Citizen
The six-story Women & Childrens Tower under construction on the hospitals West 86th Street campus will feature both private neonatal intensive care unit rooms and pediatric intensive care unit rooms. (IBJ photo/Eric Learned)
In the past five years, the nations largest Catholic health system, Ascension, has unloaded more than a dozen hospitals across the country, from New York to Alabama, as it restructures amid a growing tide of red ink.
In Indiana alone, it shut a critical-access hospital in Bedford, closed 11 immediate-care walk-in centers in central Indiana and shut down or repurposed five small neighborhood hospitals.
And theres no sign the sell-off is over.
Ascension continues selling spree, said a headline last month in Beckers Hospital Review, a trade news site, which added that the St. Louis-based system has more deals in the pipeline.
Ascension hastens exit out of Michigan, said a headline in Crains Detroit this month, after the health care system sold three hospitals in the northern part of the state to a large health system affiliated with the University of Michigan and set up a joint venture with another large system in the Detroit area.
Ascension, trying to dig itself out from a $3billion operating loss in fiscal year 2023, has not limited its sell-off to hospitals. It has also sold its interest in laboratory operations and a health insurance group.
So does Ascension plan to close or sell more Indiana assets?
In an unusual move for a national hospital system amid a major restructuring, Ascension disclosed part of its plans. It is not considering offloading or closing any more Indiana operations, an Ascension corporate spokeswoman told IBJ in an email.
The changes to our footprint in other parts of our national ministry are designed to ensure sustainable and favorable options for those communities, the email said. There are no plans to make any such changes to our Indiana ministry.
Several health care consultants said they would be shocked if Ascension sold a large number of properties in Indiana or exited the state altogether, as it has done elsewhere.
I wouldnt just be surprised. I would be totally aghast, said Ed Abel, retired director of health care practice at Indianapolis-based Blue & Co., an accounting and consulting firm. I would just say its never going to happen.
Thats because Indiana is one of the systems most profitable operations, delivering $192million in net income for the system for the fiscal year ending June 30, 2022, the most recent Indiana figures available. The same year, the system as a whole lost $879million from operations.
Translation: Indiana is a moneymaker for Ascension, helping it to fund a huge system that otherwise would be posting much larger losses.
So any further cost-cutting in Indiana would be relatively minor, some experts say.
In general, large health systems are constantly tweaking their portfolios, said David Blish, director of health care consulting for Katz Sapper & Miller, an Indianapolis-based accounting and consulting firm. I doubt Indiana Ascension will contract at a significant scale.
Ascension pointed to its flagship campus on West 86th Street, where construction continues on $325million worth of improvements, including a new brain and spine center, a new womens and childrens tower, and a new parking garage.
The company said the investments will help the companys operations here, known as Ascension St. Vincent Indiana, a premier destination for care in the Midwest.
Separately, Ascension St. Vincent this week issued invitations for a public celebration marking the 50th anniversary of the companys West 86th Street hospital. It said the event will take place 2-4 p.m. April 28 on top of the parking garage at the corner of Harcourt Drive and Katie Knox Drive.
The 50th anniversary of our 86th Street location gives us the opportunity to honor all of those who contributed to making the hospital what it is today as well as look forward to the future of health care, the invitation said.
The event will mark the 1974 move, when staff of St. Vincent and the U.S. Army Reserves transferred 102 patients from the hospitals Fall Creek campus (now part of Ivy Tech Community College) to a new campus on the northwest side of Indianapolis, which was then largely fields and forest.
Twenty-five years later, in 1999, Ascension bought St. Vincent for an undisclosed amount.
That marked the end of more than a century of independent ownership, since four nuns from the Daughters of Charity religious order arrived in Indianapolis in 1881 at the invitation of Catholic Bishop Francis Chatard and set up St. Vincent Infirmary in a house near Vermont and East streets.
Within a few years, the infirmary grew to 50 beds and changed its named to St. Vincent Hospital. It relocated twice before the move to West 86th Street. After decades of expansion, that campus now fills the better part of 20 square blocks between West 86th and West 79th streets.
Ascension said the six-story Women & Childrens Tower going up on the south side of the campus is designed to address the high level of maternal and infant mortality in Indianapolis. It will feature 109 private neonatal intensive care unit rooms along with an expanded pediatric intensive care unit. The tower is scheduled to be completed this year.
The four-story Brain and Spine Hospital is rising at the front of the campus and will include operating rooms, an intensive care unit, an intensive care step-down unit, and a residency training program. Ascension said it expects construction to be completed early next year.
The new projects, announced in 2021, represent one of the largest capital investments in decades for Ascension Indiana. It also gave the strong suggestion that the corporate parent was committed to the Indianapolis flagship, a major anchor on the busy West 86th Street commercial corridor.
So why is Ascension building here while unloading hospitals elsewhere and exiting some states altogether?
In many cases, the answer seems to be that Ascension is leaving where it cannot take advantage of a wide system of community hospitals in coordination with a top-tier hospital to handle complex cases.
In modern health care, hospital systems increasingly want a network of hospitals that can act as feeders for the major hospital in a large metropolitan area. And if they are a small player in a market that is dominated by a huge competitor, they have less chance to fill beds, negotiate favorable insurance plans and make money.
In Minnesota, the world-famous Mayo Clinic dominates the market with net patient revenue of $3.32billion in 2022far ahead of second place University of Minnesota Medical Center, which pulled in $1.68billion.
Who is ever going to beat the Mayo Clinic there? Abel said. Yes, theres a lot of competition up there. But theres a lot that have dropped out and said, Were never going to be as good as those guys.
Central Indiana has no single dominant player. Instead, there are four or five large players and a few dozen small players, mostly in the suburbs. And each system has a different claim to fame.
In the nine-county metropolitan area, Ascension St. Vincent has the most staffed beds, with 1,995, ahead of Indiana University Health (1,514), Community Health Network (1,124), Franciscan Health Network (563) and Eskenazi Health (333), according to IBJ research. (Those figures are from 2022, the most recent year available.)
Yet in the same year, Indiana University Health pulled in far more revenue across its statewide system, $8.1billion, than Ascension St. Vincent ($3.7billion) and Community Health ($3.1billion).
Statewide, Ascension owns 19 hospitals from Anderson to Brazil, including facilities in Carmel, Fishers, Indianapolis, Anderson and Kokomo.
In addition to being a large player, Ascension St. Vincent is performing well financially in central Indiana and has no reason to start offloading assets, Abel said.
Indiana is what I would call an aircraft carrier for Ascension, he said. They have a huge presence here, and theyre proud of it.
And Ascensions corporate leadership clearly has a soft spot for Indiana. The companys CEO, Joseph Impicciche, was raised in Crawfordsville and earned his bachelors at Wabash College. He went on to earn a law degree and a master of health administration degree from Indiana University. He practiced for more than a decade at Indianapolis law firm Hall Render Killian Heath & Lyman, which specializes in health care law.
Ascension declined to make Impicciche or any other senior leader available for an interview with IBJ.
Go here to see the original:
The total prize pool for the first 2024 WoW Eve Ascension tournament will be $10,000. The event will also feature five bounties worth $200 each. As for the second WoW Eve Ascension tournament, details for it will be revealed on a later date, according to Team Liquid.
View post:
Team Liquid Eve Ascension enters World of Warcraft! | esports.gg - Esports.gg
image:
Although the specificity of CRISPR-based gene-editing is highly accurate and versatile, the efficiency of installing those edits has been low. In this paper, the Adamson lab describes a more efficient prime editor. Illustration by Caitlin Sedwick for Princeton University.
Credit: Caitlin Sedwick for Princeton University
By Caitlin Sedwick for the Princeton University Department of Molecular Biology
Through years of engineering gene-editing systems, researchers have developed a suite of tools that enable the modification of genomes in living cells, akin to genome surgery. These tools, including ones based on a natural system known as CRISPR/Cas9, offer enormous potential for addressing unmet clinical needs, underscored by the recent FDA approval of the first CRISPR/Cas9-based therapy. A relatively new approach called prime editing enables gene-editing with exceptional accuracy and high versatility, but has a critical tradeoff: variable and often low efficiency of edit installation. In other words, while prime edits can be made with high precision and few unwanted byproducts, the approach also often fails to make those edits at reasonable frequencies. In a paper that appeared in print in the journal Nature on April 18th, 2024, Princeton scientists Jun Yan and Britt Adamson, along with several colleagues, describe a more efficient prime editor.
Prime editing systems minimally consist of two components: a modified version of the protein element of CRISPR/Cas9 and a ribonucleic acid (RNA) molecule called a pegRNA. These components work together in several coordinated steps: First, the pegRNA binds the protein and guides the resulting complex to a desired location in the genome. There, the protein nicks the DNA and, using a template sequence encoded on the pegRNA, reverse transcribes an edit into the genome nearby. In this way, prime editors write exact sequences into targeted DNA.
"Prime editing is such an incredibly powerful genome editing tool because it gives us more control over exactly how genomic sequences are changed, Adamson said.
At the outset of their study, Adamson and Yan, a graduate student in Adamsons research group and the Department of Molecular Biology, reasoned that unknown cellular processes may aid or hinder prime editing. To identify such processes, Yan laid out a conceptually simple plan: First, he would engineer a cell line that would emit green fluorescence when certain prime edits were installed. Then, he would systematically block expression of proteins normally expressed within those cells and measure editing-induced fluorescence to determine which of those proteins impact prime editing. By executing this plan, the team identified 36 cellular determinants of prime editing, only one of whichthe small RNA-binding protein Lapromoted editing.
Although promoting prime editing is obviously not a normal function of the La protein, our experiments showed that it can strongly facilitate the process, Yan said.
Within cells, La is known to bind specific sequences often found at the ends of nascent small RNA molecules and it protects those RNAs from degradation. The Princeton team recognized right away that the pegRNAs deployed in Yans first experiments likely contained those exact sequences, called polyuridine tracts, as they are a typical but often overlooked byproduct of pegRNA expression in cells. Subsequent experiments suggested that such pegRNAs inadvertently harness Las end-binding activity for protection and to promote prime editing.
Motivated by their results, the team asked if fusing the part of La that binds polyuridine tracts to a standard prime editing protein could boost prime editing efficiencies. They were thrilled to find that the resulting protein, which they call PE7, substantially enhanced intended prime editing efficiencies across conditions and, when using some prime editing systems, left the frequencies of unwanted byproducts very low. Their results quickly drew the attention of colleagues interested in using prime editing in primary human cells, including Daniel Bauer at Boston Childrens Hospital and Harvard Medical School and Alexander Marson at the University of California, San Francisco. Together with scientists from these labs, the team of researchers went on to demonstrate that PE7 can also enhance prime editing efficiencies in therapeutically relevant cell types, offering expanded promise for future clinical applications.
"This work is a beautiful example of how deeply probing the inner workings of cells can lead to unexpected insights that may yield near-term biomedical impact, Bauer noted.
Citation: Jun Yan, Paul Oyler-Castrillo, Purnima Ravisankar, Carl C. Ward, Sbastien Levesque, Yangwode Jing, Danny Simpson, Anqi Zhao, Hui Li, Weihao Yan, Laine Goudy, Ralf Schmidt, Sabrina C. Solley, Luke A. Gilbert, Michelle M. Chan, Daniel E. Bauer, Alexander Marson, Lance R. Parsons & Britt Adamson.Improving prime editing with an endogenous small RNA-binding protein.Nature. 2024. DOI: https://doi.org/10.1038/s41586-024-07259-6
Funding for this work was provided by the National Institutes of Health (NIH) (R35GM138167, RM1HG009490, T32HG003284, DP2CA239597, UM1HG012660 [Princeton QCB training grant; NHGRI],and [T32GM007388 Princeton MOL training grant; NIGMS]); the Searle Scholars Program; thePrinceton Catalysis Initiative; CHDI Foundation; Princeton University; the Parker Institute for Cancer Immunotherapy (PICI); the Lloyd J. Old STAR award from the Cancer Research Institute (CRI); the Simons Foundation; the CRISPR Cures for Cancer Initiative; the Arc Institute; CRUK/NIH (OT2CA278665 and CGCATF-2021/100006); Pew-Stewart Scholars for Cancer Research award; the Doris Duke Foundation; the St Jude Childrens Research Hospital Collaborative Research Consortium; NHLBI (R01HL150669); the Fred Hutch Cooperative Center of Excellence in Hematology (U54 DK106829); the China Scholarship Council (CSC), based on the April 2015 Memorandum of Understanding between the CSC and Princeton University; the NCI (K00CA245718); and the Princeton University Flow Cytometry Resource Facility (NCI-CCSG P30CA072720-5921).
Experimental study
Improving prime editing with an endogenous small RNA-binding protein
3-Apr-2024
B.A. is an advisory board member with options for Arbor Biotechnologies and Tessera Therapeutics. B.A. holds equity in Celsius Therapeutics. L.A.G has filed patents on CRISPR tools and CRISPR functional genomics and is a co-founder of Chroma Medicine. A.M. is a co-founder of Arsenal Biosciences, Site Tx, Spotlight Therapeutics, and Survey Genomics, serves on the boards of directors at Site Tx, Spotlight Therapeutics and Survey Genomics, is a member of the scientific advisory boards of Arsenal Biosciences, Site Tx, Spotlight Therapeutics, Survey Genomics, NewLimit, Amgen, Tenaya, and Lightcast, owns stock in Arsenal Biosciences, Site Tx, Spotlight Therapeutics, NewLimit, Survey Genomics, PACT Pharma, Tenaya, and Lightcast, and has received fees from Arsenal Biosciences, Spotlight Therapeutics, Site Tx NewLimit, Survey Genomics, Gilead, 23andMe, PACT Pharma, Juno Therapeutics, Tenaya, Lightcast, Trizell, Vertex, Merck, Amgen, Genentech, AlphaSights, Rupert Case Management, Bernstein, GLG, ClearView Healthcare Partners, and ALDA. A.M. is an investor in and informal advisor to Offline Ventures and a client of EPIQ. The Marson Laboratory has received research support from Juno Therapeutics, Epinomics, Sanofi, GlaxoSmithKline, Gilead, and Anthem. C.C.W. and R.S. are co-founders of Site Tx. J.Y. and B.A. have filed a patent application on aspects of this work through Princeton University, and B.A. has previously filed other patents on CRISPR-based technologies. The remaining authors declare no competing interests.
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.
More:
A small factor makes a big impact on genome editing - EurekAlert
Fellow at the Genetic Engineering and Society (GES) Center of the North Carolina State University Joseph Opoku Gakpo is urging Ghanas National Biosafety Authority (NBA) to step up its communications efforts on genetically modified organisms (GMOs).
Speaking at a webinar organised by the Africa Genetic Biocontrol Consortium on "gaps, challenges, and innovations in science communication, he said recent media reports in which some stakeholders condemned the approval of 14 genetically engineered products in the country could have been avoided through proactive communication.
A report by the United States Department for Agriculture published last month disclosed the authority has approved 14 new GMOs including eight corn events and six soybean events.
The report drew backlash from some groups including the Peasant Farmers Association, Ghana Agricultural Workers Union, Ghana Journalists for Environment, Science, Health and Agriculture (GJESHA), and the Centre for Climate Change and Food Security (CCCFS), among others.
The Peasant Farmers Association warned its members will not accept any GMO seeds under the governments flagship Planting for Food and Jobs programme.
The authority subsequently clarified in a statement that the approval is for the GMOs to be imported for use as feed, food, and for processing, and not for local cultivation.
Mr. Gakpo questioned why the authority did not find it necessary to inform Ghanaians about the approval early in the year, and waited until a foreign entity told the story first.
The approval was in February. The USDA report was published on 20th March and has been making rounds on various social media platforms.
"It wasnt until April 14 before the NBA issued a statement clarifying what it had done. How will Ghanaians feel about hearing of this approval first from a foreign partner? he quizzed.
The NBA should have been the first to put a statement, at least on its website, explaining what exactly it had done and not have created a situation where other institutions had to tell their story for them, Mr Gakpo said.
So, there wasnt proactive communication. It was simply reactive communication. And even the reactive communication happened almost a month later. The authority needs to step up its communications efforts, he added.
Mr. Gakpo whose research at the GES Center focuses on how communication influences the deployment of agricultural biotechnologies noted the National Biosafety Act 2011 which governs the operations of the NBA urges it to prioritise proactive communication.
Section 4 (d) of Act 831 says one of the functions of the authority is to promote public awareness, participation and education concerning the activities of the authority under this Act he said.
Section 41(2) also says the Authority shall publish notices of final decisions concerning applications made under this Act in the Gazette and the electronic and print media, he explained.
Mr. Gakpo said the law passed by parliament recognises the important role of the media in helping disseminate information on genetic technologies and the authority must do more in that regard.
I am not saying the Biosafety Authority is shirking its responsibility to communicate. Because I have seen officials from the authorities do media interviews and other such communication activities.
"But I am only saying they need to do more. And they should particularly be proactive rather than always fighting back, he added.
Cecilia Lubanga who is a communication specialist at the Office of the Senate in Kenya also told the webinar the field of communicating science is changing quickly and actors in the industry need to be abreast with the latest developments.
Science communication is a rapidly evolving field, driven by advancements in technology, changes in societal attitudes, and the effective dissemination of complex scientific information to diverse audiences, she said.
DISCLAIMER: The Views, Comments, Opinions, Contributions and Statements made by Readers and Contributors on this platform do not necessarily represent the views or policy of Multimedia Group Limited.
Original post:
National Biosafety Authority urged to step up its communication efforts on GMOs - Myjoyonline
Selbyville, Delaware, April 22, 2024 (GLOBE NEWSWIRE) -- DNA Synthesis Market size is expected to reach a remuneration of USD 20.5 billion by 2032. Rising advancements in biotechnology and genetic engineering across various research, diagnostic, and therapeutic applications will augment the industry growth.
Request for a sample of this research report @ https://www.gminsights.com/request-sample/detail/6000
With the rise of precision medicine and personalized healthcare, there is a growing need for custom-designed DNA sequences tailored to specific research objectives or patient requirements. For instance, in March 2024, global genomics solutions provider Integrated DNA Technologies (IDT) expanded its gene synthesis offerings by introducing a new custom vector onboarding tool. The advancing fields of synthetic biology and gene editing techniques, such as CRISPR-Cas9 have further propelled the demand for DNA synthesis, as researchers seek to engineer novel organisms and develop innovative therapies for various diseases.
Collaborations between academic institutions, biotechnology companies, and pharmaceutical firms are also facilitating the development of cutting-edge technologies and streamlined workflows in DNA synthesis. These partnerships foster innovation and knowledge exchange, driving advancements in the methodologies while expanding the repertoire of available synthetic DNA products. Furthermore, the increasing affordability and accessibility of DNA synthesis services, coupled with improvements in synthesis throughput and scalability are democratizing access to synthesized DNA for researchers worldwide.
Rising usage for diagnostics
DNA synthesis market share from the therapeutic application segment is slated to gain momentum through 2024-2032. This is driven by the increasing adoption of molecular diagnostics for disease detection and personalized treatment approaches. Custom-designed DNA sequences help in the development of molecular diagnostic tests, enabling precise detection of genetic mutations and biomarkers associated with various diseases. The advent of targeted therapies and gene editing technologies has also fueled the demand for synthesized DNA in therapeutic applications.
CRO segment to gain traction
The DNA synthesis market from the contract research organization (CRO) segment is expected to expand exponentially up to 2032. This is driven by specialized expertise and infrastructure for DNA synthesis services for catering to the diverse needs of pharmaceutical, biotechnology, and academic research institutions. These organizations possess state-of-the-art facilities equipped with high-throughput synthesis platforms and experienced scientific teams capable of delivering custom-designed DNA sequences with precision and efficiency. CROs also provide end-to-end solutions, including gene synthesis, cloning, and sequence verification, allowing clients to focus on their core research objectives while entrusting the synthesis process to specialized professionals.
Asia Pacific to emerge as a prominent industry
Asia Pacific DNA synthesis market is estimated to record significant valuation by 2032, attributed to the increasing investment in genomics research and biotechnology initiatives by governments and private enterprises across countries like China, Japan, and India. The rising prevalence of genetic disorders and infectious diseases in the region has spurred the demand for customized DNA sequences for diagnostic and therapeutic applications. Advancements in healthcare infrastructure and the growing adoption of precision medicine will further stimulate the regional industry growth.
Request for Report Customization @https://www.gminsights.com/roc/6000
DNA Synthesis Industry Players
Some of the prominent DNA synthesis market players include Thermo Fisher Scientific, Inc., ELISA experts, Twist Bioscience, BOSTER antibody, Bioneer Corporation, ProteoGenix, Eton Bioscience, BIOMATIK, LGC Biosearch Technologies, ProMab Biotechnologies, IBA GmbH, Eurogentec, Eurofins Scientific, Quintara Biosciences OriGene Technologies, Inc., Integrated DNA Technologies, Inc.and GenScript Biotech Corporation.
These firms are focusing on partnership ventures and innovations to proliferate their product portfolio and customer base. To cite an instance, in August 2023, Genscript Biotech formed a strategic collaboration agreement with T-MAXIMUM Biotech to develop CAR-T cell therapy.
Partial Table of Contents (ToC) of the report:
Chapter 2Executive Summary
2.1 Global DNA synthesis market 360 synopsis, 2018 2032 2.1.1 Business trends 2.1.2 Regional trends 2.1.3 Service trends 2.1.4 Method trends 2.1.5 Application trends 2.1.6 End-use trends Chapter 3DNA Synthesis Industry Insights 3.1 Industry ecosystem analysis 3.2 Industry impact forces 3.2.1 Growth drivers 3.2.1.1Growing prevalence of diseases globally 3.2.1.2Rapid technology advancements in the field of synthetic biology 3.2.1.3Rising investments towards research and development(R&D) activities 3.2.2 Industry pitfalls & challenges 3.2.2.1Stringent government regulations and guidelines 3.2.2.2High cost, potential biosafety,biosecurity and ethical issues 3.3 Growth potential analysis 3.3.1 By service 3.3.2 By method 3.3.3 By application 3.3.4 By end use 3.4 COVID- 19 impact analysis 3.5 Regulatory landscape 3.5.1 U.S. 3.5.2 Europe 3.6 Porter's analysis 3.7 PESTEL analysis
Browse Our Reports Store - GMIPulse @ https://www.gminsights.com/gmipulse
About Global Market Insights
Global Market Insights Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider, offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy, and biotechnology.
Read more here:
DNA Synthesis Market to hit USD 20.5 Bn by 2032, says Global Market Insights Inc. - GlobeNewswire
Researchers from the Netherlands have reported an extremely long Covid-19 infection in a man who died last year and warn of the emergence of more dangerous variants of the coronavirus.
The elderly man, who was immunocompromised due to previous illnesses, was admitted to a hospital in Amsterdam in February 2022 with a Covid-19 infection, according to a statement.
He was continuously positive for the coronavirus until his death in October 2023 for a total of 613 days.
Other cases of very long infections in people whose immune systems were unable to adequately fight the virus have previously been reported.
01:29
Like drinking milk tea: China launches worlds first inhalable Covid vaccine
Like drinking milk tea: China launches worlds first inhalable Covid vaccine
The researchers led by Magda Vergouwe from the University of Amsterdam plan to present the results at a congress of the European Society for Clinical Microbiology and Infectious Diseases in Barcelona on April 27-30.
The case is also interesting for researchers because the coronavirus can change particularly strongly in such long-term infected people. This harbours the risk of variants of the virus emerging that can more easily overcome the immune systems of healthy people.
The researchers in the Netherlands repeatedly took samples from the man to analyse the genetic material of the coronavirus. They found a total of more than 50 mutations compared to the Omicron variant BA.1 that was circulating at the time, including those that would allow the virus to evade the immune defence.
Just 21 days after the man had received a certain anti-coronavirus drug, the virus also developed signs of resistance to it.
German with comically large number of Covid jabs 217 had no side effects
The man eventually died from a flare-up of one of his previous illnesses. As far as is known, he had not infected anyone with his mutated version of the coronavirus, also known under its scientific name Sars-CoV-2.
This case highlights the risk of new immune-evasive Sars-CoV-2 variants emerging in immunocompromised patients, the researchers are quoted as saying in the press release.
The extensive development of the virus in a single patient could lead to the emergence of unique variants, they warn.
It is important to closely monitor the evolution of the coronavirus in immunocompromised individuals. There is a risk that variants could emerge and spread in society that are less susceptible to the immune systems of healthy people, they added
Read the rest here:
A new reportby Dutch scientists revealed a very peculiar case: On Feb. 2022, a 72-year-old man with a compromised immune system was admitted to Amsterdam University Medical Center with aCOVID-19infection. The virus in his body proceeded to evolve over the course of 613 days, leading to a highly mutated variant that ultimately killed him.
According to the study, the man, whose identity was not disclosed, suffered from a blood disorder. Despite receiving multiple doses of the SARS-CoV-2 vaccine, his compromised immune system made him unable to generate a detectable antibody response, allowing the virus to continue to evolve into a "novel immune-evasive variant" that had mutated over 50 times. The man died from his underlying blood disorder after fighting COVID for nearly two years, the scientists from the University of Amsterdams Centre for Experimental and Molecular Medicine stated.
This case underscores the risk of persistent SARS-CoV-2 infections in immunocompromised individuals as unique SARS-CoV-2 viral variants may emerge due to extensive intra-host evolution," the study authors stated ina press release. "We emphasize the importance of continuing genomic surveillance of SARS-CoV-2 evolution in immunocompromised individuals with persistent infections given the potential public health threat of possibly introducing viral escape variants into the community.
While the study notes there have been cases in which people have tested positive for COVID-19 for hundreds of days, this case is the longest reported by far. Furthermore, researchers say the rare variant found in this patient hasn't been reported in anyone else, but emphasize the need for more study to protect the public from potential new variants.
The researchers say they plan to further present this study at the European Society of Clinical Microbiology and Infectious Diseases Global Congress in Barcelona, Spain, startingthis weekend.
The rest is here:
Man dies after 613-day COVID-19 infection that underwent 50 mutations - Scripps News
Abbott Diagnostics Scarborough, Inc.: BinaxNOW COVID-19 Ag Card Home Test
Abbott Diagnostics Scarborough, Inc.: BinaxNOW COVID-19 Antigen Self Test
Access Bio, Inc.: CareStart COVID-19 Antigen Home Test
Alternate brand name:
ACON Laboratories, Inc: Flowflex COVID-19 Antigen Home Test
Alternate brand name:
Aptitude Medical Systems Inc.: Metrix COVID-19 Test
Celltrion USA, Inc.: Celltrion DiaTrust COVID-19 Ag Home Test
CorDx, Inc. CorDx TyFast Flu A/B & COVID-19 At Home Multiplex Rapid Test
CTK Biotech, Inc.: ImmuView COVID-19 Antigen Home Test
Cue Health Inc.: Cue COVID-19 Test for Home and Over The Counter (OTC) Use
Ellume Limited: Ellume COVID-19 Home Test
Genabio Diagnostics Inc.: Genabio COVID-19 Rapid Self-Test Kit
iHealth Labs, Inc.: iHealth COVID-19 Antigen Rapid Test
Alternate brand name:
InBios International Inc: SCoV-2 Ag Detect Rapid Self-Test
Immunostics Inc.: Swab-N-Go Home Test COVID-19 Ag
PfizerInc: Lucira CHECK-IT COVID-19 Test Kit
Maxim Biomedical, Inc.: MaximBio ClearDetect COVID-19 Antigen Home Test
Mologic, Inc.: COVI-Go SARS-CoV-2 Ag Self-Test
OraSure Technologies, Inc.: InteliSwab COVID-19 Rapid Test
OSANG LLC: OHC COVID-19 Antigen Self Test
Alternate brand name:
OSANG LLC: QuickFinder COVID-19/Flu Antigen Self Test
PHASE Scientific International, Ltd.: INDICAID COVID-19 Rapid Antigen At-Home Test
Quidel Corporation: QuickVue At-Home OTC COVID-19 Test
Alternative Brand Names:
SD Biosensor, Inc.: Pilot COVID-19 At-Home Test
FDA Safety Communication - Recall of Certain Lots
Siemens Healthineers: CLINITEST Rapid COVID-19 Antigen Self-Test
Watmind USA: Speedy Swab Rapid COVID-19 Antigen Self-Test
Xiamen Boson Biotech Co., Ltd.: Rapid SARS-CoV-2 Antigen Test Card
SEKISUI Diagnostics, LLC.: OSOM COVID-19 Antigen Home Test
Beijing Hotgen Biotech Co., Ltd.: Hotgen COVID-19 Antigen Home Test
CorDX, Inc.: CorDx COVID-19 Ag Test
Azure Biotech Inc.: Fastep COVID-19 Antigen Home Test
Oceanit Foundry LLC: ASSURE-100 Rapid COVID-19
Advin Biotech Inc.: Advin COVID-19 Antigen Test @Home
GenBody Inc.: GenBody COVID-19 Ag Home Test
Azure Biotech, Inc.: Azure FaStep COVID-19 Antigen Pen Home Test
Pfizer Inc.: Lucira by Pfizer COVID-19 & Flu Home Test
Princeton BioMeditech Corp: Status COVID-19 Antigen Rapid Test for Home Use
Nano-Ditech Corporation: Nano-Check COVID-19 Antigen At-Home Test
BioTeke USA, LLC: Bio-Self COVID-19 Antigen Home Test
3EO Health, Inc.: 3EO Health COVID-19 Test
SEKISUI Diagnostics, LLC: OSOM Flu SARS-CoV-2 Combo Home Test
Read the rest here:
General Information About At-Home OTC COVID-19 Diagnostic Tests - FDA.gov